Tumor necrosis factor (TNF)-α plays a key role in the pathogenesis of chronic inflammatory disorders; the discovery of TNF-blockers, neutralizing its biological activities, opened the way to a new efficacious therapeutic strategy. Unfortunately, the immunogenicity of anti-TNF drugs may trigger an adverse immune response with the occurrence of anti-drug antibodies (ADAs) impairing drug efficacy and safety. The increase of drug doses to overcome the effect of ADAs gives rise to many adverse effects inducing to the treatment discontinuation
Grossi, V., Infantino, M., Manfredi, M., Basile, U., Gulli, F., Marino, M., Li Gobbi, F., Damiani, A., Atzeni, F., Benucci, M., Anti-adalimumab and anti-certolizumab antibodies titers after discontinuation of adalimumab: Two case reports, <<CLINICAL CHEMISTRY AND LABORATORY MEDICINE>>, 2019; 2019 (Oct 30): 950-953. [doi:10.1515/cclm-2019-0950] [http://hdl.handle.net/10807/145072]
Anti-adalimumab and anti-certolizumab antibodies titers after discontinuation of adalimumab: Two case reports
Basile, Umberto
;Marino, Mariapaola;
2019
Abstract
Tumor necrosis factor (TNF)-α plays a key role in the pathogenesis of chronic inflammatory disorders; the discovery of TNF-blockers, neutralizing its biological activities, opened the way to a new efficacious therapeutic strategy. Unfortunately, the immunogenicity of anti-TNF drugs may trigger an adverse immune response with the occurrence of anti-drug antibodies (ADAs) impairing drug efficacy and safety. The increase of drug doses to overcome the effect of ADAs gives rise to many adverse effects inducing to the treatment discontinuation
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
